GlaxoSmithKline
NEWS
When the pandemic hit, many companies diverted resources aimed at HIV to COVID-19, which ended up pausing some research efforts.
The company, which isn’t expected to enter the clinic until possibly in 2022, is working to make cell therapies work in solid tumors.
It was another busy week for clinical trial announcement. Here’s a look.
GSK said the sale of Innovia stock would help GSK invest in other “strategic priorities,” likely those aimed at plans to separate into two main offerings over the next couple of years.
X-Vax Technology is ready to submit an IND application to the U.S. FDA for its experimental herpes vaccine against HSV-1 and -2. Here’s what you need to know.
Medicago and GSK announced their positive interim data from a mid-range study of a plant-based vaccine for COVID-19.
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.
Work-at-home arrangements created to respond to the COVID-19 pandemic have forced numerous companies in most sectors to reevaluate their work deals. This has also resulted in rethinking site locations and real estate needs. Here’s a look.
JOBS
IN THE PRESS